results: overall, there were no significant differences between groups in the primary outcome or in any of the secondary cardiovascular outcomes: 172 women in the hormone group and 176 women in the placebo group had mi or chd death (relative hazard [rh], 0.99; 95% confidence interval [ci], 0.80-1.22).